Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

from Health and Science https://ift.tt/LCUy5mf
https://ift.tt/5f4i1KD
https://ift.tt/Q0t9dGK